Search Results

Nexcella, Inc. (“Nexcella”, “Company”, “We” or “Us”), announced that effective today, Edward J. Borkowski, former Chief Financial Officer of Mylan N.V, has been appointed to the Company’s Board of Directors.

Nexcella, Inc., a subsidiary of Immix Biopharma, Inc., announced that effective today, Edward J. Borkowski, former Chief Financial Officer of Mylan N.V, has been appointed to the Company’s Board of Directors.

Johnson & Johnson and Momenta Pharmaceuticals have filed a patent infringement lawsuit over a generic multiple sclerosis drug developed by India-based Natco, Gland Pharma and Mylan.

The U.S. Court of Appeals for the Federal Circuit denied Biogen a second look into the patent dispute filed against Mylan for Biogen’s Multiple Sclerosis (MS) drug, Tecfidera.

Biogen Inc. (Nasdaq: BIIB) today announced that the European Commission has revoked the centralized marketing authorizations for generic versions of Biogen’s product TECFIDERA® (dimethyl fumarate) held by Accord, Mylan, Neuraxpharm, Polpharma and Teva.

Mylan N.V. and Pfizer Inc. announced that the U.S. Federal Trade Commission accepted a proposed consent order, which concludes the FTC’s review of the proposed combination of Mylan and Pfizer’s Upjohn Business.

The Mylan N.V. (NASDAQ: MYL) Board of Directors today announced the appointment of Robert J. Coury , previously chairman of the Mylan Board, to the position of executive chairman of Mylan. Given the unprecedented current operating environment due to the COVID-19 pandemic, the extensive ongoing activity

Mylan N.V. (Nasdaq: MYL) today announced that its shareholders overwhelmingly voted to approve the proposed transaction combining Mylan and Upjohn, a division of Pfizer, at the company’s extraordinary general meeting of shareholders.

Pfizer and Mylan are less than two weeks away from finalizing the merger of the generic drugmaker with Pfizer’s Upjohn business unit.

Pfizer Inc. (NYSE: PFE) announced today that it has completed the transaction to spin off its Upjohn Business and combine it with Mylan N.V. to form Viatris Inc. Pfizer Chairman and Chief Executive Officer Dr. Albert Bourla said, “We are proud to have completed the combination of Upjohn and Mylan to create Viatris and pleased to have delivered value to our shareholders through this transaction. I want to express my gratitu